Wenhe Zhong

Wenhe Zhong

Auto-generated profile, based on publicly available information

Wenhe Zhong

Antimicrobial Resistance Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology, 1 CREATE Way, 138602, Singapore; NTU Institute of Structural Biology, Nanyang Technological University, 636921, Singapore

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2019 in ACS Infectious Diseases
Verified
Journal Article
Open access
WZWenhe Zhong
Wenhe Zhong
AKAnn Koay
Ann Koay
ANAnna Ngo
Anna Ngo
Yan LiYan Li
Yan Li
QNQianhui Nah
Qianhui Nah
PDPeter Dedon
Peter Dedon
Bacterial tRNA modification synthesis pathways are critical to cell survival under stress and thus represent ideal mechanism-based targets for antibiotic development. One such target is the tRNA-(N1G37) methyltransferase (TrmD), which is conserved and essential in many bacterial pathogens. Here we developed and applied a widely applicable, radioactivity-free, bioluminescence-based high-throughput screen (HTS) against 116350 compounds from structurally diverse small-molecule libraries to identify inhibitors of Pseudomonas aeruginosa TrmD (PaTrmD). Of 285 compounds passing primary and secondary screens, a total of 61 TrmD inhibitors comprised of more than 12 different chemical scaffolds were identified, all showing submicromolar to low micromolar enzyme inhibitor constants, with binding affinity confirmed by thermal stability and surface plasmon resonance. S-Adenosyl-l-methionine (SAM) competition assays suggested that compounds in the pyridine-pyrazole-piperidine scaffold were substrate SAM-competitive inhibitors. This was confirmed in structural studies, with nuclear magnetic resonance analysis and crystal structures of PaTrmD showing pyridine-pyrazole-piperidine compounds bound in the SAM-binding pocket. Five hits showed cellular activities against Gram-positive bacteria, including mycobacteria, while one compound, a SAM-noncompetitive inhibitor, exhibited broad-spectrum antibacterial activity. The results of this HTS expand the repertoire of TrmD-inhibiting molecular scaffolds that show promise for antibiotic development.

23 August 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
WZWenhe Zhong
Wenhe Zhong
KPKalyan Kumar Pasunooti
Kalyan Kumar Pasunooti
SBSeetharamsing Balamkundu
Seetharamsing Balamkundu
YWYee Hwa Wong
Yee Hwa Wong
QNQianhui Nah
Qianhui Nah
Peter DedonPeter Dedon
Peter Dedon
Among the >120 modified ribonucleosides in the prokaryotic epitranscriptome, many transfer RNA (tRNA) modifications are critical to bacterial survival, which makes their synthetic enzymes ideal targets for antibiotic development. Here we performed a structure-based design of inhibitors of tRNA-(N1G37) methyltransferase, TrmD, which is an essential enzyme in many bacterial pathogens. Based on crystal structures of TrmDs from Pseudomonas aeruginosa and Mycobacterium tuberculosis, we synthesized a series of thienopyrimidinone derivatives with nanomolar potency against TrmD in vitro and discovered a novel active site conformational change triggered by inhibitor binding. This tyrosine-flipping mechanism is unique found in P. aeruginosa TrmD and renders the enzyme inaccessible to the co-factor S-adenosyl-L-methionine (SAM) and probably to the substrate tRNA. Biophysical and biochemical structure-activity relationship studies provided insights into the mechanisms underlying the potency of thienopyrimidinones as TrmD inhibitors, with several derivatives found to be active against Gram-positive and mycobacterial pathogens. These results lay a foundation for further development of TrmD inhibitors as antimicrobial agents.

9 August 2019 in RNA
Verified
Journal Article
Open access
PDF file
JJJuthamas Jaroensuk
Juthamas Jaroensuk
YWYee Hwa Wong
Yee Hwa Wong
WZWenhe Zhong
Wenhe Zhong
CLChong Wai Liew
Chong Wai Liew
SMSomchart Maenpuen
Somchart Maenpuen
MFMayuree Fuangthong
Mayuree Fuangthong
The tRNA (m1G37) methyltransferase TrmD catalyzes m1G formation at position 37 in many tRNA isoacceptors and is essential in most bacteria, which positions it as a target for antibiotic development. In spite of its crucial role, little is known about TrmD in Pseudomonas aeruginosa (PaTrmD), an important human pathogen. Here we present detailed structural, substrate, and kinetic properties of PaTrmD. The mass spectrometric analysis confirmed the G36G37-containing tRNAs Leu(GAG), Leu(CAG), Leu(UAG), Pro(GGG), Pro(UGG), Pro(CGG), and His(GUG) as PaTrmD substrates. Analysis of steady-state kinetics with S-adenosyl-l-methionine (SAM) and tRNALeu(GAG) showed that PaTrmD catalyzes the two-substrate reaction by way of a ternary complex, while isothermal titration calorimetry revealed that SAM and tRNALeu(GAG) bind to PaTrmD independently, each with a dissociation constant of 14 ± 3 µM. Inhibition by the SAM analog sinefungin was competitive with respect to SAM (Ki = 0.41 ± 0.07 µM) and uncompetitive for tRNA (Ki = 6.4 ± 0.8 µM). A set of crystal structures of the homodimeric PaTrmD protein bound to SAM and sinefungin provide the molecular basis for enzyme competitive inhibition and identify the location of the bound divalent ion. These results provide insights into PaTrmD as a potential target for the development of antibiotics.

1 November 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
WZWenhe Zhong
Wenhe Zhong
KLKuohan Li
Kuohan Li
QCQixu Cai
Qixu Cai
Jingjing GuoJingjing Guo
Jingjing Guo
MYMeng Yuan
Meng Yuan
JLJulien Lescar
Julien Lescar